Health and Healthcare

Short Sellers Run for Cover From Major Biotechs

Chris Lange

Published: May 11, 2016 8:15 am

Last Updated: January 13, 2020 9:34 am

The short interest data are out for the April 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.

The April 29 short interest data have been compared with the previous report, and short interest moves were mixed in these selected stocks.

Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 7.36 million shares from the previous level of 8.85 million. Shares closed most recently at $157.24, in a 52-week trading range of $130.09 to $181.81.

Biogen Inc. (NASDAQ: BIIB) had its short interest decrease to 1.95 million shares from the previous level of 2.12 million. Shares closed Tuesday at $273.27, within a 52-week range of $242.07 to $420.99.

24/7 Wall St.
The 5 Most Shorted Nasdaq Stocks: Short Sellers Still Cautious